TCR-T cell therapy can overcome gene suppression and enhance anti-tumor immune responses, and its application in human antigen-specific cytotoxic T lymphocytes can improve the anti-tumor function of PD-1 deleted cells (Zhang et al., 2018). This evidence concerns the gene PDCD1 and neoplasm.